[Autograft of bone marrow following intensive treatment in acute lymphoid leukemia in children]. 1985

E Plouvier, and P Hervé, and A Noir, and M Flesch, and J Y Cahn, and E Racadot, and P Henon, and P Lutz, and A Boilletot, and C Behar

Ten children were autografted for ALL in second complete remission (CR). The conditioning regimen consisted of cyclophosphamide (60 mg/kg/day X 2) and total body irradiation (10 to 13.2 grays). It was well tolerated, no deaths occurred during the first 3 months post-graft. Nine children remained in second CR, without any maintenance therapy, from 2 to 40 months after ABMT and the median survival time was 11 months. One child died 112 days post-graft, following a cerebral hemorrhage (thrombocytopenia less than 10 X 10(9) platelets/liter). One girl, affected by B ALL, was autografted while in first CR after intensive chemotherapy (modified BACT) 5 months after diagnosis. She relapsed 8 months later. Seven bone marrows have been purged ex vivo by chemotherapy (ASTA-Z) and 3 by anti-CALLA monoclonal antibodies and complement.

UI MeSH Term Description Entries
D007945 Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts. Leukemia, Lymphocytic,Lymphocytic Leukemia,Lymphoid Leukemia,Leukemias, Lymphocytic,Leukemias, Lymphoid,Lymphocytic Leukemias,Lymphoid Leukemias
D008297 Male Males
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006410 Hematopoiesis The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY). Hematopoiesis, Medullary,Haematopoiesis,Medullary Hematopoiesis

Related Publications

E Plouvier, and P Hervé, and A Noir, and M Flesch, and J Y Cahn, and E Racadot, and P Henon, and P Lutz, and A Boilletot, and C Behar
January 1985, The American journal of pediatric hematology/oncology,
E Plouvier, and P Hervé, and A Noir, and M Flesch, and J Y Cahn, and E Racadot, and P Henon, and P Lutz, and A Boilletot, and C Behar
December 2015, Leukemia research,
E Plouvier, and P Hervé, and A Noir, and M Flesch, and J Y Cahn, and E Racadot, and P Henon, and P Lutz, and A Boilletot, and C Behar
August 1988, European journal of haematology,
E Plouvier, and P Hervé, and A Noir, and M Flesch, and J Y Cahn, and E Racadot, and P Henon, and P Lutz, and A Boilletot, and C Behar
December 1973, Pediatriia,
E Plouvier, and P Hervé, and A Noir, and M Flesch, and J Y Cahn, and E Racadot, and P Henon, and P Lutz, and A Boilletot, and C Behar
September 1994, The Journal of pediatrics,
E Plouvier, and P Hervé, and A Noir, and M Flesch, and J Y Cahn, and E Racadot, and P Henon, and P Lutz, and A Boilletot, and C Behar
June 2001, Blood,
E Plouvier, and P Hervé, and A Noir, and M Flesch, and J Y Cahn, and E Racadot, and P Henon, and P Lutz, and A Boilletot, and C Behar
November 1992, Bone marrow transplantation,
E Plouvier, and P Hervé, and A Noir, and M Flesch, and J Y Cahn, and E Racadot, and P Henon, and P Lutz, and A Boilletot, and C Behar
January 1996, La Revue du praticien,
E Plouvier, and P Hervé, and A Noir, and M Flesch, and J Y Cahn, and E Racadot, and P Henon, and P Lutz, and A Boilletot, and C Behar
January 2005, Cancer,
E Plouvier, and P Hervé, and A Noir, and M Flesch, and J Y Cahn, and E Racadot, and P Henon, and P Lutz, and A Boilletot, and C Behar
August 1981, Orvosi hetilap,
Copied contents to your clipboard!